ERBB2 and non-small cell lung carcinoma: For instance, a case of advanced chemotherapy-resistant NSCLC, carrying the somatic V855A ERBB3-mutation homologous to L858R EGFR-activating mutation was reported, but its oncogenic effect in human and murine cell lines required concomitant overexpression of wt ERBB2 [165], which per se can be oncogenic and thereby confounds these results.